1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Drugs In Development, 2022, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bladder Cancer (Oncology) pipeline guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 20, 112, 117, 3, 9, 116, 22 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 6, 1, 1, 15 and 3 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Bladder Cancer - Overview
- Bladder Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bladder Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bladder Cancer - Companies Involved in Therapeutics Development
- Bladder Cancer - Drug Profiles
- Bladder Cancer - Dormant Projects
- Bladder Cancer - Discontinued Products
- Bladder Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Bladder Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Bladder Cancer - Dormant Projects, 2022
- Bladder Cancer - Discontinued Products, 2022
- Number of Products under Development for Bladder Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4C Biomed Inc
- 4D Pharma Plc
- 4SC AG
- A28 Therapeutics Inc
- Aadi Bioscience Inc
- AB Pharma Ltd
- AbbVie Inc
- Abivax SA
- Acepodia Inc
- Acrivon Therapeutics Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Advaxis Inc
- Advenchen Laboratories LLC
- Agenus Inc
- Aktis Oncology Inc
- Alligator Bioscience AB
- Alloplex Biotherapeutics Inc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Amgen Inc
- Amrita Therapeutics
- Andes Biotechnologies
- Angex Pharmaceutical Inc
- Apexian Pharmaceuticals Inc
- APIM Therapeutics AS
- Apollomics Inc
- Aprea Therapeutics Inc
- Aravive Inc
- Archivel Farma SL
- Arcus Biosciences Inc
- Asieris Pharmaceuticals Co Ltd
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aura Biosciences Inc
- Aurigene Discovery Technologies Ltd
- Aurora Oncology Inc
- Avacta Life Sciences Ltd
- AvenCell Europe GmbH
- BacoCure
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beijing Neoantigen Biotechnology Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- BerGenBio ASA
- BeyondSpring Inc
- Bicycle Therapeutics Plc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- Biocad
- Biohaven Pharmaceutical Holding Company Ltd
- BioMed Valley Discoveries Inc
- Biomics Biotechnologies Co Ltd
- BioNTech SE
- Bioven Group
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Bolt Biotherapeutics Inc
- BoYen Therapeutics Inc
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CanBas Co Ltd
- Cantargia AB
- Catalent Inc
- Catalym GmbH
- CDR-Life Inc
- CellCentric Ltd
- Celldex Therapeutics Inc
- Celon Pharma SA
- Celprogen Inc
- CG Oncology Inc
- CheckPoint Immunology Inc
- Chengdu Keen Biotechnology Co Ltd
- CicloMed LLC
- Clover Biopharmaceuticals Ltd
- CMG Pharmaceutical Co Ltd
- Codiak BioSciences Inc
- Compass Therapeutics Inc
- Convalife
- Corvus Pharmaceuticals Inc
- CStone Pharmaceuticals Co Ltd
- Cugene Inc
- Curigin Co Ltd
- Cyclacel Pharmaceuticals Inc
- Cytodyn Inc
- CytoImmune Therapeutics Inc
- CytomX Therapeutics Inc
- D3 Bio Inc
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Duet Therapeutics Inc
- Ectin Research AB
- Eddingpharm Inc
- Eisai Co Ltd
- Elevation Oncology Inc
- Eli Lilly and Co
- Elpis Biopharmaceuticals Corp
- Elucida Oncology Inc
- Emtora Biosciences
- ENB Therapeutics LLC
- enGene Inc
- EpimAb Biotherapeutics Inc
- Exelixis Inc
- EXUMA Biotech Inc
- F. Hoffmann-La Roche Ltd
- Fidia farmaceutici SpA
- FKD Therapies Oy
- For-Robin Inc
- Fujifilm Holdings Corp
- Fusion Pharmaceuticals Inc
- G1 Therapeutics Inc
- Gene Signal International SA
- Genentech USA Inc
- Genexine Inc
- Genmab AS
- Gilead Sciences Inc
- GLG Pharma SA
- GlycoNex Inc
- GlyTherix Ltd
- GO Therapeutics Inc
- Green Cross LabCell Corp
- GSK plc
- H3 Biomedicine Inc
- Hamlet Pharma AB
- Hangzhou DAC Biotech Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harpoon Therapeutics Inc
- Hefei Hankemab Biotechnology Co Ltd
- Hope Biosciences LLC
- Horizon Therapeutics Plc
- HRYZ (ShenZhen) Biotech Co
- Huabo Biopharm (Shanghai) Co Ltd
- Hummingbird Bioscience Pte Ltd
- Ideaya Biosciences Inc
- Ikena Oncology Inc
- ImCheck Therapeutics SAS
- Immatics NV
- ImmunityBio Inc
- Immunomic Therapeutics Inc
- ImmunSYS Inc
- Immupharma Plc
- Imugene Ltd
- Imunon Inc
- IMV Inc
- Imvax Inc
- Incanthera Plc
- Incyte Corp
- Indaptus Therapeutics Inc
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- Intas Pharmaceuticals Ltd
- Intravacc BV
- Invectys SA
- IO Biotech Inc
- Iovance Biotherapeutics Inc
- Istari Oncology Inc
- Jacobio Pharmaceuticals Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- JSR Life Sciences LLC
- Keythera Pharmaceuticals Co Ltd
- Komipharm International Co Ltd
- Kyowa Kirin Co Ltd
- Lantern Pharma Inc
- Lepu Biopharma Co Ltd
- Liangjiang Medicine Co Ltd
- LIfT BioSciences Ltd
- Lindis Biotech GmbH
- Linnane Pharma AB
- Lipac Oncology LLC
- LipoMedix Pharmaceutical Inc
- LipoSeuticals Inc
- Longbow Immunotherapy Inc
- Loxo Oncology Inc
- Luye Pharma Group Ltd
- Lycera Corp
- Machavert Pharmaceuticals LLC
- Manhattan Biosolutions Inc
- MaxiVAX SA
- MedAnnex Ltd
- Medibiofarma SL
- Medicenna Therapeutics Corp
- Mediolanum farmaceutici SpA
- Medivir AB
- Medolife Rx Inc
- MedPacto Inc
- Merck & Co Inc
- Merck KGaA
- Midissia Therapeutics Inc
- Mirati Therapeutics Inc
- Moderna Inc
- Modra Pharmaceuticals BV
- Molecular Partners AG
- Molecular Templates Inc
- Moleculin Biotech Inc
- Morphogenesis Inc
- MorphoSys AG
- Morvus Technology Ltd
- Mustang Bio Inc
- NanoCarrier Co Ltd
- Nanology LLC
- NeoTX Therapeutics Ltd
- NewG Lab Pharma Co Ltd
- NewG Lab Pharma Inc
- NGM Biopharmaceuticals Inc
- Northwest Biotherapeutics Inc
- NovaRock Biotherapeutics Inc
- Novartis AG
- NuGenerex Immuno-Oncology Inc
- Ocellaris Pharma Inc
- Ocuphire Pharma Inc
- Ona Therapeutics SL
- Oncorus Inc
- OncoSTING LLC
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- Optimum Therapeutics LLC
- Oxford BioTherapeutics Ltd
- Pact Pharma Inc
- Pacylex Pharmaceuticals Inc
- Pan Cancer T BV
- Papyrus Therapeutics Inc
- Pfizer Inc
- Pharma Mar SA
- Pieris Pharmaceuticals Inc
- Pinotbio Inc
- Plus Therapeutics Inc
- Portage Biotech Inc
- Potenza Therapeutics Inc
- Prelude Therapeutics Inc
- Prokarium Ltd
- Propanc Biopharma Inc
- Protara Therapeutics Inc
- Provecs Medical GmbH
- PsiOxus Therapeutics Ltd
- Puma Biotechnology Inc
- Qilu Pharmaceutical Co Ltd
- Qu Biologics Inc
- Quadriga BioSciences Inc
- Qwixel Therapeutics LLC
- Ractigen Therapeutics Inc
- Rapa Therapeutics LLC
- Regeneron Pharmaceuticals Inc
- RemeGen Co Ltd
- Replimune Ltd
- Sanofi
- Sareum Holdings Plc
- Savoy Pharmaceuticals Inc
- Scholar Rock Inc
- Seagen Inc
- Serum Institute of India Pvt Ltd
- Sesen Bio Inc
- SetLance srl
- Seven and Eight Biopharmaceuticals Corp
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yuansong Biotechnology Co Ltd
- Shenyang Research Institute of Chemical Industry Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shionogi & Co Ltd
- Shorla Pharma Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Sillajen Biotherapeutics
- Sirnaomics Ltd
- SOTIO Biotech AS
- Spectrum Pharmaceuticals Inc
- Statera Biopharma Inc
- Stcube Inc
- Sumitomo Dainippon Pharma Oncology, Inc
- Syncromune Inc
- SynOx Therapeutics Ltd
- T-Cure Bioscience Inc
- TAE Life Sciences LLC
- Takeda Pharmaceutical Co Ltd
- Tango Therapeutics Inc
- Targovax ASA
- TCRx Therapeutics Co Ltd
- Tempest Therapeutics Inc
- Tessa Therapeutics Ltd
- Theralase Technologies Inc
- Tollys SAS
- Toray Industries Inc
- Transcenta Holding Ltd
- Transgene SA
- TransThera Sciences (Nanjing) Inc
- Treos Bio Ltd
- Tyra Biosciences Inc
- UbiVac Inc
- United Immunity Co Ltd
- UroGen Pharma Ltd
- VasGene Therapeutics Inc
- Vault Pharma Inc
- Vaxiion Therapeutics Inc
- Venenum Biodesign LLC
- Vivlmmune Inc
- Vyriad Inc
- Wuhan Binhui Biotechnology Co Ltd
- Xbrane Biopharma AB
- Xiangxue Life Sciences
- Zhejiang Teruisi Pharmaceutical Co Ltd
- Zhejiang Yangshengtang Biotech Co Ltd
- Zhuhai Beihai Biotech Co Ltd
